September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, ...
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings ...
Creation would no longer be only production. It would become a way of knowing. Another mind would be a mirror capable of ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) falls more steeply than broader market: What investors need to know
Recursion Pharmaceuticals (RXRX) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the ...
Don't catch a falling knife.
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.
Eunji Lim will lead the cast of THE RECURSION OF A MOTH, a new play by Brandon Zang directed by Seonjae Kim, at Teatro ...
Nvidia portfolio breakdown: every company Nvidia owns a stake in, all 8 of them, worth $63.44bn. Intel alone is 47.3%. Plus ...
Zacks Investment Research on MSN
Why Recursion Pharmaceuticals (RXRX) dipped more than broader market today
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.16, moving -1.71% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.59%.
Contineum Therapeutics, Inc.(NasdaqGS:CTNM) added to Russell 2000 Value Benchmark CI Jun. 28 Contineum Therapeutics, Inc.(NasdaqGS:CTNM) added to Russell 3000E Value Benchmark CI Jun. 28 Contineum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results